Sunday, April 5, 2026 | The Valve Wire

Executive Summary

Today's structural heart landscape centers on the practical challenges that follow valve implantation — from pacemaker selection to cardiac rehabilitation to predicting complications in bicuspid anatomy. A new meta-analysis finds that leadless pacemakers after TAVR reduce device complications but carry a higher mortality signal that likely reflects selection bias rather than device inferiority. A whole-population English study of nearly 25,000 TAVI recipients reveals that only 4.4% attend cardiac rehabilitation — a striking gap with modest outcome benefits. And a multicenter machine learning model identifies five predictors of periprocedural adverse events in bicuspid aortic valve TAVR, a population that both the ACC/AHA and ESC guidelines acknowledge remains poorly served by transcatheter approaches.

For the clinical audience: this is a day to think about the post-TAVR ecosystem. The leadless vs. transvenous pacemaker question is increasingly relevant as conduction disturbance remains TAVR's Achilles' heel — and the answer is far from settled with only retrospective data available. The cardiac rehab data from England should prompt uncomfortable questions about whether we're doing enough after the procedure. Meanwhile, the bicuspid TAVR risk model from a 1,266-patient cohort offers a useful framework, but clinicians should remember that both guideline documents rate TAVI for bicuspid valves at Class IIb — these patients were excluded from virtually all major RCTs. Separately, a JACC publication on the ICARUS concept (intentional clip annular reduction for subsequent mitral replacement) signals creative thinking about staged transcatheter mitral strategies, and a validated fluid-structure interaction model for aortic stenosis hints at the long game for computational planning in structural heart.

Today's Key Findings

[NOTABLE] Leadless vs. Transvenous Pacemakers Post-TAVR: Fewer Complications, But a Mortality Signal. A systematic review and meta-analysis of six retrospective studies (10,681 patients, 874 receiving leadless pacemakers) found that leadless pacemaker implantation after TAVR was associated with significantly fewer device-related complications (RR 0.46) and vascular access complications (RR 0.15) compared with transvenous pacemakers. However, leadless pacemakers carried a higher risk of all-cause mortality at 2 years (RR 1.61, p=0.047). The authors appropriately attribute this to selection bias in unadjusted baseline characteristics — sicker patients may have been preferentially directed to leadless devices. No difference in rehospitalization was observed. Editorial note: This is entirely retrospective data with no propensity matching in most included studies. The mortality finding should not deter leadless pacemaker use, but it underscores the urgent need for prospective, randomized comparison in the post-TAVR population. Conduction disturbance remains the most common complication of TAVR, and optimizing pacing strategy is an underappreciated aspect of procedural planning.

[NOTABLE] Cardiac Rehabilitation After TAVI: A Whole-Population Wake-Up Call. A retrospective cohort study published in Heart examined all 24,925 TAVI recipients in England from 2018–2023. Only 1,090 (4.4%) attended cardiac rehabilitation. CR participation dropped during the first COVID lockdown but rebounded. After multivariable adjustment, CR was associated with lower all-cause rehospitalization (HR 0.88) and non-cardiovascular rehospitalization (HR 0.84), but showed no significant association with heart failure rehospitalization or mortality. Editorial note: A 4.4% CR participation rate after TAVI is remarkably low and raises questions about systematic referral patterns and patient access. The lack of mortality benefit is consistent with the observational design and potential healthy-user bias — patients able to attend CR are inherently different from those who cannot. Still, the rehospitalization signal warrants attention given the healthcare cost implications. Prospective trials of structured post-TAVI rehabilitation are overdue.

[NOTABLE] Machine Learning Predicts Periprocedural Adverse Events in Bicuspid TAVR. A multicenter study published in Open Heart developed a machine learning model from 1,266 bicuspid aortic valve patients undergoing TAVR. Five predictive factors emerged: Type 0 BAV morphology, aortic root calcification volume, horizontal aorta, annular ellipticity, and prior atrial fibrillation. The model achieved an AUC of 0.801, with periprocedural adverse event rates ranging from 0.6% in the lowest-risk quartile to 9.6% in the highest. Editorial note: This is useful work, but context is critical. Both the 2020 ACC/AHA (Class IIb) and 2025 ESC (Class IIb) guidelines position TAVR for bicuspid valves as a secondary option, primarily in patients at increased surgical risk. The NOTION 2 trial showed a numerically higher event rate with TAVI in BAV patients (HR 3.8, p=0.07). A prediction model that helps identify which BAV patients are at highest risk for TAVR complications is valuable — but it should be used to identify patients who may be better served by surgery, not simply to optimize transcatheter technique in patients who might not be ideal TAVR candidates.

Aortic Valve (TAVR/TAVI)

Membranous Septum Length and Valve Calcification Predict Pacemaker Need After SAVR. A study in JTCVS of 425 SAVR patients with preoperative CT imaging found that shorter membranous septum length and higher aortic valve calcium scores were independently associated with permanent pacemaker implantation (7.5% rate). Membranous septum length had the greatest explanatory value (pseudo-R² = 0.08), exceeding even preexisting right bundle branch block. This mirrors the well-established CT-based risk stratification used in TAVR planning and supports expanding routine CT assessment to surgical candidates. This is an important contribution — the reference literature we track on conduction disturbances after SAVR in BAV patients (Okada et al.) showed BAV-AS patients had higher rates of new-onset third-degree AV block (6.5% vs 2.5%) and LBBB (9.7% vs 5.7%) compared to tricuspid valve patients. Today's study reinforces that conduction risk is modifiable through better anatomical assessment regardless of intervention type.

Transcarotid TAVR With Balloon-Expandable Valves. A report in the Journal of Cardiothoracic Surgery examines outcomes of transcarotid TAVR with balloon-expandable valves. No abstract is available, but this alternative access route is increasingly relevant as the field grapples with patients who lack suitable transfemoral anatomy — the preferred access route emphasized in both the ACC/AHA 2020 and ESC 2025 guidelines for TAVI-preferred patients.

Cusp-Overlap vs. Three-Cusps Coplanar Techniques and Conduction Disturbances. A study in Cardiovascular Intervention and Therapeutics compares the influence of cusp-overlap and three-cusps coplanar implantation techniques on new-onset conduction disturbances after TAVI. These deployment strategies represent important procedural refinements aimed at reducing the persistent problem of post-TAVR pacemaker implantation, which remains considerably higher than after SAVR — particularly with self-expanding valves.

Post-TAVI Valve Orifice Assessment by TEE. A study in Cardiovascular Intervention and Therapeutics examines anatomical valve orifice area assessment after TAVI using transesophageal echocardiography. This relates to the broader effort to standardize post-implantation hemodynamic assessment — an area highlighted by the Heart Valve Collaboratory's recent best practices framework for imaging transcatheter valve failure.

Fluid-Structure Interaction Models Validated Against 4D Flow MRI. A study in The Journal of Physiology validated patient-specific computational models of the aortic valve against in vivo 4D flow MRI data in five pre-TAVR patients. The models accurately replicated flow dynamics and enabled calculation of blood residence time — important for thrombus formation risk. This represents progress toward integrating computational modeling into clinical planning, though the sample size of five patients underscores that widespread clinical application remains distant.

Aortic Growth After Valve Replacement: BAV vs. Tricuspid. A systematic review and meta-analysis in the Portuguese Journal of Cardiology compared aortic growth rates and aortic event risk between BAV and tricuspid aortic valve patients after valve replacement. No significant difference was found in annual aortic growth (mean difference 0.15 mm/year, p=0.09), aortic dissection risk (RR 1.34, p=0.44), or reintervention (RR 0.95, p=0.84). This challenges the long-standing assumption that bicuspid morphology intrinsically accelerates post-operative aortopathy in all patients, though the high heterogeneity (I² = 82.6%) demands cautious interpretation. Current guidelines still recommend concurrent aortic surgery for significant dilation in BAV patients undergoing valve replacement.

Correspondence on TAVR vs. SAVR 5-Year Outcomes. A letter in Heart responds to previously published 5-year outcomes comparing TAVR and SAVR in low-to-intermediate surgical risk patients. While the abstract is unavailable, this type of ongoing scholarly debate reflects the field's continued reckoning with long-term comparative data — precisely the evidence gap that separates the ACC/AHA and ESC guideline positions on the TAVI age threshold (65 vs. 70 years).

Pressure-Based Assessment of Hemodynamic Improvement Post-TAVI. A newly registered trial (NCT07509554) from Istanbul will evaluate pressure-based metrics of disease improvement in 100 TAVI patients, adding to the growing body of work on real-time hemodynamic assessment during and after the procedure.

Mitral Valve (MitraClip, PASCAL, TMVR)

[NOTABLE] ICARUS: Intentional Clip Annular Reduction for Subsequent Replacement. A publication in JACC describes the ICARUS concept — using transcatheter edge-to-edge repair clips to intentionally reduce the mitral annular dimension as a bridge to subsequent transcatheter mitral valve replacement. This is a creative staged approach that acknowledges one of the central challenges in TMVR: the mitral annulus is often too large and too dynamic for current transcatheter replacement devices. By using clips to create a smaller, more anchoring-friendly orifice, ICARUS could expand the pool of patients eligible for TMVR. Editorial note: This is conceptually intriguing but raises important questions. How much residual stenosis is acceptable after clip placement? Does clip-induced geometry alteration create durable anchor points? And is a two-procedure strategy justified when surgical repair or replacement remains the gold standard with well-established outcomes? This approach makes most sense for truly inoperable patients, and we should be cautious about extrapolating it to lower-risk populations.

Iatrogenic ASD Closure After Transcatheter Mitral Valve Repair. A Cureus publication revisits the MITHRAS trial concept in a larger cohort, examining percutaneous closure of iatrogenic atrial septal defects following transcatheter mitral valve repair. Transseptal access for mitral TEER creates ASDs that usually close spontaneously, but persistent shunts can cause right heart volume overload. This is a practical procedural consideration that becomes more relevant as mitral TEER volumes increase — particularly now that the ESC 2025 guidelines have upgraded TEER for secondary MR to Class I.

MitraFix Transcatheter Mitral Valve System — First-in-Human. A newly recruiting first-in-human study (NCT07501234) of the MitraFix transcatheter mitral valve system from Mitrassist Lifesciences is enrolling 5 patients. This adds to the growing field of TMVR devices competing for a challenging anatomical niche.

Tricuspid Valve (TriClip, TTVR)

TriClip Japan Post-Approval Study Now Recruiting. The TriClip Japan Post-Approval Study (NCT07509658) is now actively recruiting 250 patients. This post-market surveillance study is important for understanding how transcatheter tricuspid repair performs in Japanese patients, whose anatomy and body habitus may differ from the predominantly Western populations studied in TRILUMINATE. The ESC 2025 guidelines gave transcatheter tricuspid treatment a Class IIa recommendation — a remarkable leap from no mention in the ACC/AHA 2020 guidelines — making real-world post-market data essential for confirming generalizability.

Surgical vs. Transcatheter Comparisons

No new head-to-head comparative studies published today, but several items inform this ongoing debate. The JTCVS study on membranous septum length demonstrates that CT-based conduction risk prediction, long established for TAVR, is equally valuable for SAVR planning — a reminder that sophisticated preprocedural imaging benefits both approaches. The ICARUS concept in JACC represents an acknowledgment that transcatheter mitral replacement still cannot match surgical options in many anatomies, requiring creative staged strategies. And the correspondence in Heart on 5-year TAVR vs. SAVR outcomes continues the dialogue on whether transcatheter approaches maintain equivalence beyond the early post-procedural period where they typically show advantage.

Device & Technology

Hemostatic Sponge for Anticoagulant-Associated Hemorrhage. A study in Advanced Healthcare Materials describes a novel gelatin sponge patch with NHS ester-functionalized polymer coating that achieves hemostasis independent of classical coagulation pathways. In heparinized rat models, the composite sponge significantly reduced bleeding time and blood loss compared with commercial sponges. While not valve-specific, this technology is directly relevant to structural heart procedures performed on anticoagulated patients — including TAVR in patients bridging from warfarin, and particularly relevant given the persistent vascular access complications that plague the field.

Guide Catheter Extension and IVUS for Aortic Paravalvular Leak Closure. A BMJ Case Reports publication demonstrates the utility of guide catheter extensions and intravascular ultrasound — tools borrowed from coronary intervention — to facilitate transcatheter closure of aortic paravalvular leak. As noted in recent Heart Valve Collaboratory guidance on imaging transcatheter valve failure, paravalvular leak management is an increasingly important aspect of the post-TAVR care continuum.

SAPIEN 3 Ultra RESILIA Long-Term Registry. A prospective registry (NCT06953206) evaluating long-term outcomes of the SAPIEN 3 Ultra RESILIA valve is in preparation, with planned enrollment of 500 patients. The RESILIA tissue treatment is Edwards Lifesciences' answer to the durability question — designed to resist calcification through anti-calcification technology. Long-term data on this platform will be critical for resolving the durability debate that underpins the SAVR vs. TAVI age threshold disagreement between ACC/AHA and ESC guidelines.

Industry & Market

Cardiac Surgery Devices Market Projected to Grow Through 2035. An IndexBox market report projects continued growth in the cardiac surgery devices market through 2035, driven by accelerating adoption of minimally invasive procedures. The report highlights the convergence of transcatheter and surgical technologies as a key growth driver — consistent with the expansion of TAVI indications in both the ESC 2025 and anticipated ACC/AHA guideline updates, as well as the emerging transcatheter tricuspid market.

Edwards Lifesciences Valuation Analysis. A Simply Wall St analysis examines whether Edwards Lifesciences is fairly priced after recent share price volatility. With earnings due April 22, investors are weighing the company's TAVR market dominance against increasing competition from Medtronic's Evolut platform and the expanding TEER/TTVR portfolio. Edwards' forward P/E of 24.48 versus its trailing P/E of 44.78 suggests the market expects significant earnings growth — a bet on continued TAVR volume expansion and EVOQUE tricuspid replacement commercialization.

Financial Analysis

The structural heart device sector enters the second week of April under significant pressure from broader market volatility, with three of the five tracked companies trading well below their 6-month highs. The story diverges sharply between pure-play structural heart companies and diversified medtech conglomerates.

Edwards Lifesciences remains the bellwether, holding relatively steady with a modest 5.16% gain over six months despite a slight pullback on April 2. The company's Q1 earnings report on April 22 looms as the sector's most important near-term catalyst. Street expectations ($0.73 EPS on $1.60B revenue) will be measured against TAVR volume trends — particularly in Europe, where the ESC 2025 guideline's lower age threshold for TAVI (70 vs. ACC/AHA's implicit 65-80 shared decision zone) could meaningfully expand the addressable market. The EVOQUE tricuspid replacement program (TRISCEND II trial actively enrolling with 864 patients) and PASCAL TEER platform represent key growth vectors beyond the core TAVR franchise. Analysts maintain a consensus "buy" with a $96.93 target, implying nearly 20% upside.

Boston Scientific has experienced the most dramatic drawdown, falling 35.45% over six months from its October high near $105. Despite the decline, the company retains a "strong buy" consensus with a target implying 60% upside — a remarkable disconnect that reflects either extreme pessimism or a conviction that the selloff is overdone. BSX's structural heart exposure through the ACURATE valve platform in TAVR and the WATCHMAN left atrial appendage closure device continues to grow, and the company's broader cardiovascular intervention portfolio provides diversification. Q1 earnings on April 22 (same day as Edwards) will be closely watched.

Abbott's 22.84% six-month decline reflects broader challenges across its diversified portfolio, but the structural heart division — home to MitraClip/TriClip TEER and the Navitor TAVR system — remains a growth engine. The TriClip Japan Post-Approval Study (recruiting, 250 patients) and the REPAIR-MR landmark trial (active, not recruiting) represent key milestones for Abbott's mitral and tricuspid franchises. Abbott reports Q1 earnings April 16, providing the first look at 2026 structural heart volumes.

Medtronic's 9.95% decline is more measured, and the company's forward P/E of 14.29 is the most value-oriented in the group. The Evolut Low Risk long-term follow-up (NCT02701283, active) and the Intrepid TMVR program (NCT03242642, recruiting 1,056 patients) are key pipeline assets. Medtronic reports later (May 20), giving management the advantage of seeing competitors' numbers first.

Anteris Technologies, the sole small-cap in the group, shows the highest 6-month return (+16.15%) but also the most volatility, dropping 4.19% on April 2 alone on extremely thin volume (1,910 shares). The DURAVALVE tissue technology remains the company's core thesis — a single-piece surgical valve designed for superior durability — but the path to commercialization remains long and capital-intensive.

The private companies in the space — JenaValve Technology (ALIGN-AR LVAD registry now recruiting), Meril Life Sciences (Myval platform, LANDMARK trial completed), and J Valve Technology — continue to advance their pipelines without public market scrutiny. JenaValve's Trilogy system for aortic regurgitation addresses a gap that both guidelines now acknowledge (ESC 2025: Class IIb for TAVI in AR), potentially offering first-mover advantage in a nascent but growing transcatheter indication.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

Close: $81.05 | Daily Change: -$0.21 (-0.26%)
6-Month Performance: +$3.98 (+5.16%)
Market Cap: $47.1B | P/E (trailing): 44.78 | P/E (forward): 24.48
Beta: 0.94 | 52-Week Range: $65.94 - $87.89
Analyst Target: $96.93 (range: $84.00 - $110.00, 27 analysts) — Buy
Next Earnings: April 22, 2026 (EPS est: $0.73 | Revenue est: $1.60B)
Edwards enters earnings season with the most to prove: TAVR volume growth, EVOQUE tricuspid launch trajectory, and PASCAL TEER expansion. The forward P/E compression from 44.78 to 24.48 reflects significant growth expectations. The SAPIEN 3 Ultra RESILIA long-term registry (500 patients planned) will be critical for defending TAVI durability claims as the ESC 2025 guidelines expand the TAVI-preferred population down to age 70.

Medtronic (MDT)

Close: $86.63 | Daily Change: +$0.57 (+0.66%)
6-Month Performance: -$9.57 (-9.95%)
Market Cap: $111.2B | P/E (trailing): 24.20 | P/E (forward): 14.29
Beta: 0.76 | 52-Week Range: $79.55 - $106.33
Analyst Target: $110.60 (range: $91.00 - $125.00, 25 analysts) — Buy
Next Earnings: May 20, 2026 (EPS est: $1.54 | Revenue est: $9.65B)
Medtronic's structural heart portfolio spans the Evolut TAVR platform and Intrepid TMVR system. The Evolut Low Risk long-term follow-up (NCT02701283) continues to generate data that informed the ESC 2025 guideline shift. The Intrepid TMVR trial (1,056 patients) remains one of the largest transcatheter mitral replacement programs globally. At a forward P/E of 14.29, MDT trades at a significant discount to Edwards, reflecting both its diversified revenue base and slower structural heart growth.

Abbott (ABT)

Close: $102.87 | Daily Change: +$0.49 (+0.48%)
6-Month Performance: -$30.45 (-22.84%)
Market Cap: $178.8B | P/E (trailing): 27.65 | P/E (forward): 16.85
Beta: 0.78 | 52-Week Range: $100.88 - $139.06
Analyst Target: $132.28 (range: $113.00 - $158.00, 25 analysts) — Buy
Next Earnings: April 16, 2026 (EPS est: $1.15 | Revenue est: $11.00B)
Abbott's structural heart division owns the MitraClip and TriClip franchises — the dominant TEER platforms for mitral and tricuspid repair. The TriClip Japan Post-Approval Study (250 patients, recruiting) and REPAIR-MR landmark trial are key pipeline milestones. Abbott's recent 22.84% decline has pushed the stock to 52-week lows near $100.88, creating what analysts see as a significant valuation gap versus the $132.28 consensus target. Q1 earnings on April 16 will be the first earnings report in the sector this cycle.

Boston Scientific (BSX)

Close: $62.82 | Daily Change: +$0.82 (+1.32%)
6-Month Performance: -$34.50 (-35.45%)
Market Cap: $93.4B | P/E (trailing): 32.38 | P/E (forward): 16.07
Beta: 0.78 | 52-Week Range: $61.25 - $109.50
Analyst Target: $100.81 (range: $83.00 - $124.00, 32 analysts) — Strong Buy
Next Earnings: April 22, 2026 (EPS est: $0.79 | Revenue est: $5.18B)
Boston Scientific's 35% six-month decline is the steepest in the group, driven by broader medtech sentiment rather than structural heart-specific concerns. The company's ACURATE TAVR platform in Europe and expanding cardiovascular intervention portfolio continue to gain share. The strong buy consensus with a 60% upside target suggests analysts view the current valuation as disconnected from fundamentals. The company hit a new 52-week low of $61.25 in the past week.

Anteris Technologies (AVR.AX)

Close: A$7.55 | Daily Change: -A$0.33 (-4.19%)
6-Month Performance: +A$1.05 (+16.15%)
Market Cap: A$0.8B | P/E (forward): -3.46 (pre-revenue)
Beta: 0.55 | 52-Week Range: A$4.26 - A$9.79
Analyst Target: A$13.00 (1 analyst)
Anteris' DURAVALVE single-piece tissue valve technology targets the durability gap that continues to cloud the TAVR vs. SAVR debate. The company remains pre-revenue with negative forward earnings, making it a high-risk, high-conviction play on next-generation valve technology. Extremely low trading volume (1,910 shares) limits price discovery reliability.

Private Companies: JenaValve Technology (Trilogy Heart Valve System for aortic regurgitation — ALIGN-AR LVAD registry recruiting 50 patients), Meril Life Sciences (Myval balloon-expandable TAVR platform — demonstrated noninferiority in the LANDMARK trial), and J Valve Technology remain privately held with no public stock data available.

Market Outlook: The structural heart sector faces a critical three-week stretch with Abbott (April 16), Edwards Lifesciences (April 22), and Boston Scientific (April 22) all reporting Q1 earnings. The key metrics will be TAVR procedure volumes (particularly in Europe post-ESC guideline expansion), TEER adoption curves for mitral and tricuspid indications, and early EVOQUE/Intrepid TMVR commercialization signals. Broader market headwinds have compressed valuations across the sector, with BSX and ABT trading at or near 52-week lows — creating potential opportunity if earnings confirm underlying structural heart growth remains intact despite macroeconomic uncertainty.

Clinical Trial Updates

Aortic Valve Trials

NCT02701283 — Evolut Low Risk (Long-term Follow-up) [LANDMARK]
- Status: Active, not recruiting | Enrollment: 2,223 | Sponsor: Medtronic Cardiovascular
- This landmark trial's long-term follow-up is generating the durability data that both guidelines reference when debating the SAVR vs. TAVI age threshold. Updated: March 19, 2026.
NCT07509554 — PRessure-based Evaluation of Disease Improvement in TAVI (PREDICT)
- Status: Not yet recruiting | Enrollment: 100 | Sponsor: Istanbul Mehmet Akif Ersoy Hospital
- New registration. Will evaluate hemodynamic improvement using pressure-based metrics post-TAVI.
NCT06953206 — SAPIEN 3 Ultra RESILIA Long-Term Evaluation
- Status: Not yet recruiting | Enrollment: 500 | Sponsor: Institut für Pharmakologie und Präventive Medizin
- Prospective registry evaluating long-term outcomes of Edwards' RESILIA tissue-treated TAVR platform — key for the durability debate.
NCT06197503 — Physiological vs RV Pacing Post-TAVI
- Status: Recruiting | Enrollment: 48 | Sponsor: Hospital Clinic of Barcelona
- Randomized study comparing conduction system pacing vs. RV pacing in patients with normal ventricular function requiring pacemakers post-TAVI. Directly relevant to today's leadless pacemaker meta-analysis.
NCT06762288 — TAP Block in TAVI
- Status: Completed | Enrollment: 50 | Sponsor: Istanbul University - Cerrahpasa
- Evaluated transversus abdominis plane block for analgesia during TAVI procedures.
NCT05326126 — Microvascular Function and Myocardial Fibrosis in TAVI
- Status: Completed | Enrollment: 75 | Sponsor: Matteo Montorfano
- Evaluated coronary microvascular function and its association with myocardial fibrosis in severe symptomatic AS patients undergoing TAVI.
NCT05750173 — EASE-IT CT Registry
- Status: Completed | Enrollment: 150 | Sponsor: Institut für Pharmakologie und Präventive Medizin
- Registry examining streamlined pre-procedural CT pathways for TAVI planning.
NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction
- Status: Not yet recruiting | Enrollment: 1,000 | Sponsor: NHLBI
- Large NHLBI-funded study on advanced CT reconstruction techniques with applications across structural heart planning.

Mitral Repair Trials

NCT04198870 — REPAIR-MR (MitraClip vs Surgery for Primary MR) [LANDMARK]
- Status: Active, not recruiting | Enrollment: 500 | Sponsor: Abbott Medical Devices
- This pivotal trial comparing MitraClip to surgical repair in primary MR is one of the most consequential ongoing studies in structural heart. Both ACC/AHA and ESC guidelines rate TEER as Class IIa for high-surgical-risk primary MR patients — this trial could fundamentally change that calculus. Last updated: November 12, 2025.
NCT05051033 — PRIMATY (MitraClip vs Medical Therapy for Secondary MR) [LANDMARK]
- Status: Recruiting | Enrollment: 450 | Sponsor: Annetine Gelijns
- Critically important trial testing whether TEER benefits extend beyond COAPT-like populations to a broader secondary MR cohort. Results will determine whether the ESC's Class I upgrade for TEER in secondary MR is validated in a US population. Updated: March 3, 2026.
NCT03706833 — COAPT (Long-term Follow-up) [LANDMARK]
- Status: Active, not recruiting | Enrollment: 1,247 | Sponsor: Edwards Lifesciences
- The trial that changed the treatment paradigm for secondary MR continues long-term follow-up. COAPT 5-year data drove the ESC 2025 upgrade to Class I for TEER in ventricular SMR. Extended follow-up on PASCAL and MitraClip arms will inform device selection. Updated: February 23, 2026.
NCT04097145 — Edwards PASCAL Transcatheter Valve Repair System Pivotal Trial
- Status: Recruiting | Enrollment: 870 | Sponsor: Edwards Lifesciences
- Large pivotal trial of the PASCAL TEER system across mitral indications. Updated: March 31, 2026.

Mitral Replacement Trials

NCT03242642 — Medtronic Intrepid TMVR System
- Status: Recruiting | Enrollment: 1,056 | Sponsor: Medtronic Cardiovascular
- One of the largest TMVR programs globally, the Intrepid system represents Medtronic's bid for the transcatheter mitral replacement market. The ESC 2025 guidelines added TMVI as Class IIb for degenerative MS with MAC. Updated: March 31, 2026.
NCT07501234 — MitraFix Transcatheter Mitral Valve System (First-in-Human)
- Status: Recruiting | Enrollment: 5 | Sponsor: Mitrassist Lifesciences
- Very early-stage feasibility study of a new TMVR device. Updated: March 30, 2026.

Tricuspid Repair Trials

NCT03904147 — TRILUMINATE Pivotal (TriClip for TR) [LANDMARK]
- Status: Active, not recruiting | Enrollment: 572 | Sponsor: Abbott Medical Devices
- The trial that put transcatheter tricuspid repair on the map. TRILUMINATE data, combined with Tri.Fr and TRISCEND II, drove the ESC 2025 Class IIa recommendation for transcatheter TR treatment — a category that didn't exist in the 2020 ACC/AHA guidelines. Last updated: December 19, 2024.
NCT07509658 — TriClip Japan Post-Approval Study
- Status: Recruiting (newly registered) | Enrollment: 250 | Sponsor: Abbott Medical Devices
- Post-market surveillance in Japan — important for understanding geographic generalizability of TRILUMINATE results. Updated: April 3, 2026.

Tricuspid Replacement Trials

NCT04482062 — TRISCEND II (Evoque Tricuspid Replacement) [LANDMARK]
- Status: Active, not recruiting | Enrollment: 864 | Sponsor: Edwards Lifesciences
- The largest transcatheter tricuspid replacement trial, TRISCEND II showed superior symptom and QoL improvement vs. medical therapy, with acknowledged trade-offs in bleeding and pacemaker rates. Updated: February 27, 2026.
NCT05848284 — VISTA-US (VDyne Transcatheter Tricuspid Valve Replacement)
- Status: Recruiting | Enrollment: 30 | Sponsor: VDyne, Inc.
- Early feasibility study of VDyne's competing TTVR system. Updated: March 31, 2026.

Other Relevant Trials

NCT06594705 — JenaValve ALIGN-AR LVAD Registry
- Status: Recruiting | Enrollment: 50 | Sponsor: JenaValve Technology
- Registry evaluating the Trilogy Heart Valve System in aortic regurgitation patients with LVADs — a unique niche where transcatheter AR treatment (ESC 2025: Class IIb) intersects with advanced heart failure. Updated: April 1, 2026.

Social & Conference Highlights

Patient Story: CBS News Features TAVR After Syncope. A CBS News feature profiles a retired grandfather who fainted during a bike ride and was subsequently diagnosed with aortic stenosis requiring TAVR. These patient stories serve an important public health function — syncope is a classic symptom of severe AS, and delayed diagnosis remains common. The ESC 2025 guidelines' expansion of early intervention to asymptomatic patients (Class IIa based on EARLY TAVR, RECOVERY, and AVATAR) underscores the push toward earlier identification and treatment.

That's the wire for today. The next three weeks will be defined by earnings season — Abbott (April 16), Edwards and Boston Scientific (April 22) — and the structural heart volumes those reports reveal. As always, the science moves faster than the guidelines, and the guidelines move faster than the evidence. Read critically.

— E. Nolan Beckett, The Valve Wire